# Regulatory penalties for Vietnamese pharmaceutical companies

> Live situation record from CLSTR: https://clstr.news/situations/regulatory-penalties-for-vietnamese-pharmaceutical-companies
> Updated: 2026-09-29T01:57:37.000Z. Sources: 5. Developments: 2.

Vietnamese pharmaceutical companies have faced regulatory penalties for financial and pricing violations.

In early September 2026, Vidipha Pharmaceutical Joint Stock Company (VDP) was ordered by the Ho Chi Minh City Tax Department to pay 812.5 million VND in tax arrears, penalties, and late payment interest. This regulatory action occurred alongside changes in the company’s shareholder structure, including the divestment of Chairman Kieu Huu’s 7.5% stake and the emergence of new major shareholders.

Later in the month, Dat Vi Phu Pharmaceutical Joint Stock Company was fined 25 million VND by the Drug Administration of Vietnam. The fine was issued for incorrect price declarations regarding the essential medicine Ozzy40, violating regulations under Decree 87/2024/ND-CP. The company was mandated to rectify its price declarations within 10 days to avoid compulsory enforcement.

## Timeline

### 2026-09-29: Dat Vi Phu Pharmaceutical fined for incorrect drug pricing

Dat Vi Phu Pharmaceutical Joint Stock Company was fined 25 million VND by Vietnam's Drug Administration for misreporting the selling price of the essential medicine Ozzy40.

4 sources. https://clstr.news/cluster/dat-vi-phu-pharmaceutical-fined-for-incorrect-drug-pricing

### 2026-09-11: Vidipha Pharmaceutical fined 812.5 million VND for tax violations

Vidipha Pharmaceutical JSC must pay 812.5 million VND in tax arrears and penalties following a decision by the Ho Chi Minh City Tax Department.

2 sources. https://clstr.news/cluster/vidipha-pharmaceutical-fined-8125-million-vnd-for-tax-violations

---
Cite as: Regulatory penalties for Vietnamese pharmaceutical companies. CLSTR, https://clstr.news/situations/regulatory-penalties-for-vietnamese-pharmaceutical-companies